Advanced gynecological cancer: Quality of life one year after diagnosis

ESGO eAcademy, Björg Jónsdóttir, 343739

Reconstructive surgery in the surgical management of VIN and VaIN

ESGO eAcademy, Pawel Knapp, 343726

Management of VaIN

ESGO eAcademy, Vesna Kesic, 343725

Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective study

ESGO eAcademy, Hanna Valstad, 343735

European enhanced recovery after surgery (ERAS) gynecological oncology survey: Current state of perioperative practice

ESGO eAcademy, Natalia R. Gómez-Hidalgo, 343743

ERAS protocols in gynaecological oncology. Should we include thoracic epidural analgesia?

ESGO eAcademy, Anastasios Pandraklakis, 343745

Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN)

ESGO eAcademy, Floriane Jochum, 343747

Short- and long-term urological complications after surgery for early-stage cervical cancer

ESGO eAcademy, María Tiermes Marina Martín, 343741

Preinvasive disease of vulva and vagina - Q&A

ESGO eAcademy, Faculty / Presenters, 343727

Loss of ovarian function in young patients with cancer: prognostic model

ESGO eAcademy, Raffaella Cioffi, 343737

Tumor cell dissemination is independent from endometrial carcinoma molecular subtypes

ESGO eAcademy, Lea Volmer, 343733

Indocyanine green to assess vascularity of ileal conduit anastomosis during pelvic exenteration for recurrent/persistent gynecological cancer

ESGO eAcademy, Nicolo Bizzarri, 343731

Palbociclib and metformin show anticancer efficacy in high grade serous ovarian cancer

ESGO eAcademy, Irina Tsibulak, 343729

Gestational Trophoblastic Disease – The need to collaborate beyond country borders - Q&A

ESGO eAcademy, Faculty / Presenters, 340953

Scientific session 14: Regional challenges in gynaecological cancer and access to care - Q&A

ESGO eAcademy, Nadeem R. Abu-Rustum, 340960

Establishing a new GTD centre: a Serbian experience

ESGO eAcademy, Vesna Kesic, 340952

Personalised treatment in gynaecological sarcoma

ESGO eAcademy, Isabelle Ray-Coquard, 340945

Challenges in gynaecological cancer care and access in developing nations

ESGO eAcademy, Jalid Sehouli, 340959

Hot news in GTD management through international collaboration

ESGO eAcademy, Michael Seckl, 340951

Rare variants of ovarian cancer

ESGO eAcademy, Elena Ioanna Braicu, 340944

Scientific session 13: Rare gynaecological tumours: How developments in pathobiology help treatment and research

ESGO eAcademy, Faculty / Presenters, 340939

Rare variants of endometrial carcinoma

ESGO eAcademy, Xavier Matias-Guiu, 340943

Elimination of Cervical Cancer European Experience

ESGO eAcademy, Artem Stepanyan, 340958

International networks for rare tumours, what the EOTTD can contribute to care and education

ESGO eAcademy, Christianne Lok, 340950

Rare gynaecological tumours: How developments in pathobiology help treatment and research - Q&A

ESGO eAcademy, Faculty / Presenters, 343722

State of the art 11: Does the tumour microenvironment hold the key to the success of immunotherapy? - Q&A

ESGO eAcademy, Faculty / Presenters, 340932

Updates on combinatorial approaches in ovarian cancer immunotherapy

ESGO eAcademy, Christian Marth, 340931

Immunological configuration of ovarian carcinoma: Impact on disease outcome and response to immunotherapy

ESGO eAcademy, Jitka Palich Fucikova, 343708

Findings and outcomes in a post-vaccination cohort of young women under 25 years attending a tertiary colposcopy service

ESGO eAcademy, Cheryl Yim, 343714

Debate 3: Management of patients with "intermediate risk" cervical cancer

ESGO eAcademy, Faculty / Presenters, 340935

Debate 3: Management of patients with "intermediate risk" cervical cancer

ESGO eAcademy, Alexandra Taylor, 340938

Resection of the upper paracervical lymphovascular tissue should be a part of a pelvic sentinel lymph node algorithm in early stage cervical cancer

ESGO eAcademy, Oscar Lührs, 343720

SENTIX -  Accuracy of preoperative local staging in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

ESGO eAcademy, Jaroslav Klat, 343718

The impact of micrometastases in cervical cancer patients - a retrospective study of the SCCAN (Surveillance in Cervical CANcer) project

ESGO eAcademy, Lukas Dostalek, 343716

Sentinel Lymph Node Mapping in Early-Stage Cervical Cancer – A National Prospective Multicentre Study (SENTIREC Trial)

ESGO eAcademy, Sara Sponholtz, 343712

State of the art 9: Are we reaching the safety limit for fertility preservation in gynaecologic malignancies? - Q&A

ESGO eAcademy, Faculty / Presenters, 340914

Prevention of burn-out for health care providers

ESGO eAcademy, Vesna Kesic, 340925

Cancer is a “WE-disease” – family and partner involvement as the main caregivers

ESGO eAcademy, Annette Hasenburg, 340924

Could we preserve fertility with any myometrial infiltration in endometrial cancer?

ESGO eAcademy, Alexandros Rodolakis, 340913

Scientific session 12: Empowering life - Q&A

ESGO eAcademy, Faculty / Presenters, 343707

Brachytherapy in gynaecological tumours (cervical, endometrial, vaginal) Q&A

ESGO eAcademy, Faculty / Presenters, 343706

Endometrial cancer. Don´t forget curative, brachytherapy-based radiotherapy when surgery is contraindicated

ESGO eAcademy, Elzbieta van der Steen-Banasik, 343705

Image-guided radiotherapy for primary vaginal cancer: Impact on disease outcome and morbidity

ESGO eAcademy, Lars Fokdal, 343704

Empowering life for patients

ESGO eAcademy, Joachim Weis, 340923

Cervical cancer: Image-guided external beam radiotherapy and brachytherapy

ESGO eAcademy, Remi Nout, 343703

Fertility preservation in ovarian cancer: safety boundaries

ESGO eAcademy, Ignacio Zapardiel, 340912

Should neoadjuvant chemotherapy be a standard in fertility sparing treatment of cervical cancer?

ESGO eAcademy, Michael Halaska, 340911

Scientific session 11: Selection of patients with relapsed ovarian cancer for surgery - Q&A

ESGO eAcademy, Faculty / Presenters, 340888

Tumour board 3: Borderline ovarian tumours: Individualising patient management - Discussion

ESGO eAcademy, Faculty / Presenters, 340906

Surgery in recurrent ovarian cancer - Improving selection process by integrating molecular biology

ESGO eAcademy, Nicole Concin, 340887

Serous borderline tumour/ low-grade serous carcinoma: oncological treatments (what and when)

ESGO eAcademy, Gourley Charlie, 340905

Surgery in recurrent ovarian cancer - Improving selection process by integrating pre-operative imaging & laparoscopy into the clinical algorithm

ESGO eAcademy, Anna Fagotti, 340886

Abdominal wall complications after GynOnc surgery - treatment and management

ESGO eAcademy, Luis Chiva, 340896

Serous borderline tumours: does implant type matter and limits of fertility-preserving surgery

ESGO eAcademy, Philippe Morice, 340904

Miscellaneous complications in GynOnc surgery - interactive workshop with case reports: diagnosis, treatment and management

ESGO eAcademy, Beyhan Ataseven, 340895

What is the State-of-the-Art: RCTs in surgery for recurrent Ovarian Cancer

ESGO eAcademy, Andreas du Bois, 340885

Pathology of borderline ovarian tumours: more than one disease

ESGO eAcademy, Glenn McCluggage, 340903

Video abstract 3 - Laterally extended pelvic resection with complete resection of ureter and nephrectomy

ESGO eAcademy, Michal Zikan, 340880

Video abstract 2 - ID 848: Indocyanine green to assess vascularity of Bricker ileal conduit anastomosis during pelvic exenteration for recurrent cervical cancer

ESGO eAcademy, Nicolo Bizzarri, 340879

Video abstract 1 - ID 1021: V-Y flap reconstruction for vulvar cancer recurrence after primary radiotherapy

ESGO eAcademy, Sergi Fernandez, 340878

Pelvic exenteration-Out of the box

ESGO eAcademy, Gwenael Ferron, 340877

Pelvic reconstruction

ESGO eAcademy, Cagatay Taskiran, 340876

Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative.

ESGO eAcademy, Stefan Kommoss, 343698

Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study

ESGO eAcademy, Ana Oaknin, 343699

Best oral - late breaking abstracts 2 - Q&A

ESGO eAcademy, Faculty / Presenters, 343702

Real-world patterns of care and outcomes in patients with microsatellite-instability high tumors in advanced endometrial cancer in the United States

ESGO eAcademy, Prabhu Vimalanand, 343700

State of the art 8: Major advances in gynaecological cancers 2021 - Discussion

ESGO eAcademy, Faculty / Presenters, 343694

Immunotherapy: New era in the management of endometrial and cervical cancers

ESGO eAcademy, Mansoor Raza Mirza, 343692

Technique of the pelvic exenteration

ESGO eAcademy, Francesco Raspagliesi, 340875

Major advances in gynaecological cancers 2021. Improving the standard of care: "More is NOT better!" -

ESGO eAcademy, Antonio Gonzalez Martin, 343691

Focus on novel therapy in gynaecological cancers

ESGO eAcademy, Domenica Lorusso, 343693

Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets

ESGO eAcademy, Lisa Vermij, 343697

Perspectives on robotic assisted surgery in Gynecology Oncology during Covid times

ESGO eAcademy, Faculty / Presenters, 340864

Scientific session 10: Immune checkpoint inhibitors- ready for the prime time in endometrial and cervical cancers? - Discussion

ESGO eAcademy, Faculty / Presenters, 340845

Tumour board 2: Management of gynaecological sarcomas - Q&A

ESGO eAcademy, Faculty / Presenters, 340853

Adjuvant treatment of uterine sarcomas and management of metastatic disease

ESGO eAcademy, Ronnie Shapira-Frommer, 340852

How to improve immunotherapy strategies in uterine cancers: combinations and beyond

ESGO eAcademy, Faculty / Presenters, 340844

ERAS and impact of evidenced-based medicine in modern ovarian cancer surgical care

ESGO eAcademy, Pedro Ramirez, 340860

Diagnosis and surgical treatment of endometrial stromal sarcoma and uterine adenosarcoma - Anything new?

ESGO eAcademy, Mehmet Mutlu Meydanli, 340851

Role of immunotherapy in advanced and recurrent cervical cancer

ESGO eAcademy, Domenica Lorusso, 340843

Hot topics of the gyanecological oncologist: summary of recommendations

ESGO eAcademy, Dimitrios Haidopoulos, 340859

Role of immunotherapy in advanced and recurrent cervical cancer

ESGO eAcademy, Domenica Lorusso, 350673

Overview of the new ESGO perioperative guidelines for ovarian cancer surgery

ESGO eAcademy, Christina Fotopoulou, 340858

How to diagnose and manage uterine leiomyosarcoma?

ESGO eAcademy, Frederic Amant, 340850

Role of immunotherapy in advanced and recurrent endometrial cancer

ESGO eAcademy, Ana Oaknin, 350672

Antibody Drug Conjugates in Treating Recurrent Ovarian Cancer: The Next Generation – A Focus on NaPi2b

ESGO eAcademy, Faculty / Presenters, 340834

State of the art 6: SLN in gynaecological tumours (State of the art 2021 and next steps) - Discussion

ESGO eAcademy, Faculty / Presenters, 340819

Scientific session 9: PARP resistance - how might this be avoided or overcome? - Discussion

ESGO eAcademy, Faculty / Presenters, 340833

How we can discuss palliation with our patients

ESGO eAcademy, Kristina Lindemann, 340826

SLN vulva update

ESGO eAcademy, Maaike Oonk, 340818

New options of therapy in patients resistant to PARPi

ESGO eAcademy, David Tan, 340832

Role of palliative surgery in ovarian cancer

ESGO eAcademy, Jalid Sehouli, 340825

SLN ultrastaging and management of ITC in uterine cancer

ESGO eAcademy, Nadeem R. Abu-Rustum, 340817

Chemotherapy options after progression to PARPi

ESGO eAcademy, Sandro Pignata, 340831

SLN uterine cancer European perspective (anatomic and surgical aspects, implementation, learning)

ESGO eAcademy, Jan Persson, 340816

Mechanisms of resistance to PARPi in ovarian cancer

ESGO eAcademy, Gourley Charlie, 350675

Mechanisms of resistance to PARPi in ovarian cancer

ESGO eAcademy, Gourley Charlie, 340830

Pro and cons of palliative chemotherapy in relapsed ovarian cancer

ESGO eAcademy, Nicoletta Colombo, 340824

Scientific session 8: Palliative strategies to optimise care in gynaecological cancer - Q&A

ESGO eAcademy, Jalid Sehouli, 340822

Presidential session and awards

ESGO eAcademy, Faculty / Presenters, 340811